Cargando…

Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation

This study was designed to determine the efficacy of a new oral anticoagulant (NOAC) therapy for the prevention of endothelial dysfunction and atherosclerosis progression in patients with atrial fibrillation (AF). Sixty-five AF patients with a CHA2DS2-VASc score ≥2 without previous history of cardio...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Gyeong-Won, Lee, Jung Myung, Choi, Seung Woo, Kim, Joan, Lee, Young Shin, Kim, Hyung Oh, Chung, Hyemoon, Woo, Jong Shin, Kim, Jin Bae, Kim, Woo-Shik, Kim, Weon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509820/
https://www.ncbi.nlm.nih.gov/pubmed/34640348
http://dx.doi.org/10.3390/jcm10194332
_version_ 1784582436845256704
author Jang, Gyeong-Won
Lee, Jung Myung
Choi, Seung Woo
Kim, Joan
Lee, Young Shin
Kim, Hyung Oh
Chung, Hyemoon
Woo, Jong Shin
Kim, Jin Bae
Kim, Woo-Shik
Kim, Weon
author_facet Jang, Gyeong-Won
Lee, Jung Myung
Choi, Seung Woo
Kim, Joan
Lee, Young Shin
Kim, Hyung Oh
Chung, Hyemoon
Woo, Jong Shin
Kim, Jin Bae
Kim, Woo-Shik
Kim, Weon
author_sort Jang, Gyeong-Won
collection PubMed
description This study was designed to determine the efficacy of a new oral anticoagulant (NOAC) therapy for the prevention of endothelial dysfunction and atherosclerosis progression in patients with atrial fibrillation (AF). Sixty-five AF patients with a CHA2DS2-VASc score ≥2 without previous history of cardiovascular disease were registered and randomly assigned to either an NOAC group (dabigatran or rivaroxaban) or the warfarin group. Reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements reflecting endothelial function were taken using Endo-PAT2000. Carotid intima–media thickness (IMT) was measured at baseline, 12 months, and 24 months, and several biomarkers were also analyzed. For the primary end point, the reactive hyperemia index (RHI) for the NOAC group was 1.5 ± 0.4 and that for the warfarin group was 1.6 ± 0.5. The left and right carotid IMT was 0.7 mm in the NOAC groups and 0.8 mm in the warfarin group. At 12 months, RHI was 1.6 ± 0.3 for the dabigatran group, 1.6 ± 0.5 for the rivaroxaban group, and 1.6 ± 0.3 for the warfarin group. The three groups did not differ statistically with respect to change in left and right carotid IMT at 12 and 24 months, respectively. The biomarkers for endothelial function and atherosclerosis were not significantly different. There was a trend of reduced P-selectin levels in the NOAC group compared to the warfarin group. In patients with AF, there were no significant differences in the prevention of endothelial dysfunction and atherosclerosis progression between the NOAC and warfarin groups.
format Online
Article
Text
id pubmed-8509820
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85098202021-10-13 Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation Jang, Gyeong-Won Lee, Jung Myung Choi, Seung Woo Kim, Joan Lee, Young Shin Kim, Hyung Oh Chung, Hyemoon Woo, Jong Shin Kim, Jin Bae Kim, Woo-Shik Kim, Weon J Clin Med Article This study was designed to determine the efficacy of a new oral anticoagulant (NOAC) therapy for the prevention of endothelial dysfunction and atherosclerosis progression in patients with atrial fibrillation (AF). Sixty-five AF patients with a CHA2DS2-VASc score ≥2 without previous history of cardiovascular disease were registered and randomly assigned to either an NOAC group (dabigatran or rivaroxaban) or the warfarin group. Reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements reflecting endothelial function were taken using Endo-PAT2000. Carotid intima–media thickness (IMT) was measured at baseline, 12 months, and 24 months, and several biomarkers were also analyzed. For the primary end point, the reactive hyperemia index (RHI) for the NOAC group was 1.5 ± 0.4 and that for the warfarin group was 1.6 ± 0.5. The left and right carotid IMT was 0.7 mm in the NOAC groups and 0.8 mm in the warfarin group. At 12 months, RHI was 1.6 ± 0.3 for the dabigatran group, 1.6 ± 0.5 for the rivaroxaban group, and 1.6 ± 0.3 for the warfarin group. The three groups did not differ statistically with respect to change in left and right carotid IMT at 12 and 24 months, respectively. The biomarkers for endothelial function and atherosclerosis were not significantly different. There was a trend of reduced P-selectin levels in the NOAC group compared to the warfarin group. In patients with AF, there were no significant differences in the prevention of endothelial dysfunction and atherosclerosis progression between the NOAC and warfarin groups. MDPI 2021-09-23 /pmc/articles/PMC8509820/ /pubmed/34640348 http://dx.doi.org/10.3390/jcm10194332 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jang, Gyeong-Won
Lee, Jung Myung
Choi, Seung Woo
Kim, Joan
Lee, Young Shin
Kim, Hyung Oh
Chung, Hyemoon
Woo, Jong Shin
Kim, Jin Bae
Kim, Woo-Shik
Kim, Weon
Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation
title Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation
title_full Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation
title_fullStr Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation
title_full_unstemmed Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation
title_short Vascular Protective Effects of New Oral Anticoagulants in Patients with Atrial Fibrillation
title_sort vascular protective effects of new oral anticoagulants in patients with atrial fibrillation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509820/
https://www.ncbi.nlm.nih.gov/pubmed/34640348
http://dx.doi.org/10.3390/jcm10194332
work_keys_str_mv AT janggyeongwon vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation
AT leejungmyung vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation
AT choiseungwoo vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation
AT kimjoan vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation
AT leeyoungshin vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation
AT kimhyungoh vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation
AT chunghyemoon vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation
AT woojongshin vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation
AT kimjinbae vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation
AT kimwooshik vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation
AT kimweon vascularprotectiveeffectsofneworalanticoagulantsinpatientswithatrialfibrillation